Establishment Labs (NASDAQ:ESTA) Stock Price Expected to Rise, Mizuho Analyst Says

Establishment Labs (NASDAQ:ESTA) had its price objective lifted by Mizuho from $58.00 to $70.00 in a report published on Wednesday morning,Benzinga reports. Mizuho currently has an outperform rating on the stock.

A number of other research firms have also recently commented on ESTA. Citigroup increased their price target on Establishment Labs from $38.00 to $47.00 and gave the company a “neutral” rating in a research note on Wednesday, July 9th. Wall Street Zen lowered Establishment Labs from a “hold” rating to a “sell” rating in a report on Saturday, July 12th. BTIG Research started coverage on Establishment Labs in a report on Friday, May 16th. They issued a “buy” rating and a $62.00 price objective on the stock. Finally, Needham & Company LLC reissued a “buy” rating and issued a $48.00 price objective on shares of Establishment Labs in a research note on Friday, June 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $54.83.

Establishment Labs Stock Performance

NASDAQ:ESTA opened at $41.57 on Wednesday. The business has a 50 day moving average price of $39.19 and a 200-day moving average price of $36.90. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $50.85. The firm has a market cap of $1.20 billion, a PE ratio of -13.41 and a beta of 0.80. The company has a debt-to-equity ratio of 5.72, a quick ratio of 2.05 and a current ratio of 3.36.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.13. Establishment Labs had a negative return on equity of 196.25% and a negative net margin of 52.34%. The company had revenue of $41.38 million during the quarter, compared to the consensus estimate of $41.15 million. During the same period last year, the company earned ($0.58) EPS. Establishment Labs’s revenue for the quarter was up 11.3% on a year-over-year basis. Equities research analysts predict that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Investors Weigh In On Establishment Labs

A number of hedge funds have recently bought and sold shares of the company. Guided Capital Wealth Management LLC raised its holdings in shares of Establishment Labs by 13.2% during the second quarter. Guided Capital Wealth Management LLC now owns 49,742 shares of the company’s stock worth $2,124,000 after acquiring an additional 5,789 shares during the period. Mudita Advisors LLP increased its stake in shares of Establishment Labs by 15.6% during the 1st quarter. Mudita Advisors LLP now owns 479,359 shares of the company’s stock worth $19,560,000 after purchasing an additional 64,859 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Establishment Labs by 20.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock worth $2,335,000 after purchasing an additional 9,557 shares during the last quarter. Boothbay Fund Management LLC boosted its holdings in shares of Establishment Labs by 0.6% during the 1st quarter. Boothbay Fund Management LLC now owns 528,308 shares of the company’s stock worth $21,558,000 after buying an additional 3,060 shares during the period. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Establishment Labs during the 1st quarter worth about $326,000. 72.91% of the stock is currently owned by institutional investors.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.